[{"address1": "Jinchuang Plaza", "address2": "Building 1, Fourth Floor 4560 Jinke Road Pudong", "city": "Shanghai", "zip": "201210", "country": "China", "phone": "86 21 6163 2588", "website": "https://www.zailaboratory.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-na\u00efve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.", "fullTimeEmployees": 2175, "companyOfficers": [{"maxAge": 1, "name": "Dr. Ying  Du Ph.D.", "age": 57, "title": "Founder, Chairperson & CEO", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 1698822, "exercisedValue": 11985000, "unexercisedValue": 57389912}, {"maxAge": 1, "name": "Mr. Joshua L.  Smiley", "age": 53, "title": "President & COO", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 1223640, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Rafael G.  Amado M.D.", "age": 59, "title": "President and Head of Global Research & Development", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 1601060, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yajing  Chen Ph.D.", "age": 55, "title": "Chief Financial Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 624562, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter  Huang Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Christine  Chiou", "title": "Senior VP & Head of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Frazor Titus  Edmondson III, J.D.", "age": 57, "title": "Chief Legal Officer & Joint Corporate Secretary", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 829003, "exercisedValue": 0, "unexercisedValue": 4122300}, {"maxAge": 1, "name": "Ms. Ann E.  Beasley J.D.", "title": "Chief Compliance Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ning  Xu M.D.", "age": 58, "title": "Executive VP & Head of Clinical Operations", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jonathan J.  Wang MBA, Ph.D.", "age": 41, "title": "Chief Business Officer", "yearBorn": 1982, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 18.74, "open": 18.95, "dayLow": 18.69, "dayHigh": 19.48, "regularMarketPreviousClose": 18.74, "regularMarketOpen": 18.95, "regularMarketDayLow": 18.69, "regularMarketDayHigh": 19.48, "beta": 1.054, "forwardPE": -10.681818, "volume": 669065, "regularMarketVolume": 669065, "averageVolume": 611303, "averageVolume10days": 585094, "averageDailyVolume10Day": 585094, "bid": 18.75, "ask": 18.83, "bidSize": 200, "askSize": 200, "marketCap": 1916998272, "fiftyTwoWeekLow": 13.48, "fiftyTwoWeekHigh": 32.6, "priceToSalesTrailing12Months": 6.5860157, "fiftyDayAverage": 18.7154, "twoHundredDayAverage": 21.334225, "currency": "USD", "enterpriseValue": 17971464192, "profitMargins": -1.16448, "floatShares": 890362955, "sharesOutstanding": 99117504, "sharesShort": 2821191, "sharesShortPriorMonth": 2709916, "sharesShortPreviousMonthDate": 1717113600, "dateShortInterest": 1719532800, "sharesPercentSharesOut": 0.028499998, "heldPercentInsiders": 0.02164, "heldPercentInstitutions": 0.52838004, "shortRatio": 4.9, "bookValue": 7.831, "priceToBook": 2.400715, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -338947008, "trailingEps": -3.5, "forwardEps": -1.76, "pegRatio": 0.08, "enterpriseToRevenue": 61.743, "enterpriseToEbitda": -48.839, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ZLAB", "underlyingSymbol": "ZLAB", "shortName": "Zai Lab Limited", "longName": "Zai Lab Limited", "firstTradeDateEpochUtc": 1505914200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "8abb8ada-ed23-324a-aac0-9a720ac3e08a", "gmtOffSetMilliseconds": -14400000, "currentPrice": 18.8, "targetHighPrice": 66.0, "targetLowPrice": 21.0, "targetMeanPrice": 53.71, "targetMedianPrice": 61.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 9, "totalCash": 650780032, "totalCashPerShare": 0.659, "ebitda": -367976000, "totalDebt": 63349000, "quickRatio": 3.782, "currentRatio": 4.626, "totalRevenue": 291071008, "debtToEquity": 8.312, "revenuePerShare": 3.003, "returnOnAssets": -0.21853, "returnOnEquity": -0.38442, "freeCashflow": -225874624, "operatingCashflow": -218996992, "revenueGrowth": 0.388, "grossMargins": -0.306, "ebitdaMargins": -1.26421, "operatingMargins": -0.80677, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-19"}]